Neurology Central

Parkinson’s drug trial authorized by the Medicines Agency of Sweden

The Medicines Agency of Sweden has authorized a Phase I-II clinical study for the investigation of cerebral dopamine neurotrophic factor (CDNF) and Renishaw’s (UK) chronic drug delivery system as a treatment for Parkinson’s disease (PD).
To view restricted content, please:

Leave A Comment